Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Socié, Gérard  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Djeghloul D, Kuranda K, Kuzniak I, Barbieri D, Naguibneva I, Choisy C, Bories J-C, Dosquet C, Pla M, Vanneaux V, et al. Age-Associated Decrease of the Histone Methyltransferase SUV39H1 in HSC Perturbs Heterochromatin and B Lymphoid Differentiation. Stem Cell Reports. 2016;6(6):970-984.
Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen--A Report From the Acute Leukemia Worki. J Clin Oncol. 2013.
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EWA, Vonk MC, Schattenberg AV, et al. Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial. JAMA. 2014;311(24):2490-2498.
Cheng G-S, Bondeelle L, Gooley T, He Q, Jamani K, Krakow EF, Flowers MED, de Latour RPeffault, Michonneau D, Socié G, et al. Azithromycin use and increased cancer risk among patients with bronchiolitis obliterans after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019.
C
Maffini E, Labopin M, Blaise D, Ciceri F, Gulbas Z, Deconinck E, Leblond V, Chevallier P, Socié G, Araujo MColorado, et al. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European. Am J Hematol. 2020.
Meppiel E, Crassard I, de Latour RPeffault, de Guibert S, Terriou L, Chabriat H, Socié G, Bousser M-G. Cerebral Venous Thrombosis in Paroxysmal Nocturnal Hemoglobinuria: A Series of 15 Cases and Review of the Literature. Medicine (Baltimore). 2015;94(1):e362.
Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, et al. Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
Paviglianiti A, Labopin M, Blaise D, Socié G, Bulabois CEric, Lioure B, Ceballos P, Blau IWolfgang, Guillerm G, Maertens J, et al. Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. Bone Marrow Transplant. 2020.
Peric Z, Labopin M, Peczynski C, Polge E, Cornelissen J, Carpenter B, Potter M, Malladi R, Byrne J, Schouten H, et al. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2020.
Itzykson R, Robin M, Moins-Teisserenc H, Delord M, Busson M, Xhaard A, de Fontbrune FSicre, de Latour RPeffault, Toubert A, Socié G. Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. Haematologica. 2014.
E
Bondeelle L, Chevret S, Hurabielle C, Samy L, Goletto T, Costantini A, de Fontbrune FSicre, Michonneau D, Socié G, Tazi A, et al. Effect of Ruxolitinib on lung function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Zeiser R, Socié G, Schroeder MA, Abhyankar S, Vaz CPinho, Kwon M, Clausen J, Volodin L, Giebel S, Chacon MJurado, et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 2022;9(1):e14-e25.
Brüggen M-C, Petzelbauer P, Greinix H, Contassot E, Jankovic D, French L, Socié G, Rabitsch W, Kuzmina Z, Kalhs P, et al. Epidermal Elafin Expression is an Indicator of Poor Prognosis in Cutaneous Graft-versus-Host Disease. J Invest Dermatol. 2014.
Fayard A, Daguenet E, Blaise D, Chevallier P, Labussière H, Berceanu A, Yakoub-Agha I, Socié G, Charbonnier A, Suarez F, et al. Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell. Bone Marrow Transplant. 2019.
Tichelli A, Beohou E, Labopin M, Socié G, Rovó A, Badoglio M, van Biezen A, Bader P, Duarte RF, Basak G, et al. Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients. JAMA Oncol. 2018.
F
Payen M, Nicolis I, Robin M, Michonneau D, Delannoye J, Mayeur C, Kapel N, Berçot B, Butel M-J, Le Goff J, et al. Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. Blood Adv. 2020;4(9):1824-1832.
G
O'Meara A, Boukouaci W, Robin M, Xhaard A, Fortier C, Marzais F, de Fontbrune FSicre, de Latour RPeffault, Charron D, Socié G, et al. GLCCI1 and GR genetic diversity and response to glucocorticoid-based treatment of graft-versus-host disease. Biol Blood Marrow Transplant. 2015.
Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, Ciceri F, Gedde-Dahl T, Meijer E, Niittyvuopio R, et al. Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplant Cell Ther. 2021.
H
Bazarbachi A, Labopin M, Angelucci E, Gulbas Z, Ozdoğu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, et al. Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
Beaussant Y, Daguindau E, Pugin A, Mohty M, Avet-Loiseau H, Roos-Weil D, Michallet M, Chevalier P, Raus N, El-Cheikh J, et al. Hematopoietic stem cell transplantation in multiple myeloma. A retrospective study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Biol Blood Marrow Transplant. 2015.
Loschi M, Porcher R, de Latour RPeffault, Vanneaux V, Robin M, Xhaard A, de Fontebrune FSicre, Larghero J, Socié G. High Number of memory T cells is associated with higher risk Of acute GVHD after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014.
Giannoni L, Morin F, Robin M, Peyneau M, Schlageter MHélène, Desmier D, Pagliuca S, Del Galy ASutra, de Fontbrune FSicre, Xhaard A, et al. Human-derived α1-antitrypsin is still efficacious in heavily pretreated patients with steroid-resistant gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2020.
I
Glauzy S, Soret J, Fournier I, Douay C, Moins-Teisserenc H, de Latour RPeffault, Maki G, Robin M, Socié G, Toubert A, et al. Impact of acute and chronic Graft-vs-Host Disease on human B-cell generation and replication. Blood. 2014.
Qayed M, Michonneau D, Socié G, Waller EK. Indole derivatives, microbiome and graft versus host disease. Curr Opin Immunol. 2021;70:40-47.

Pages